1. Scrip
  2. >>Archive

Seroquel-Nurofen Plus mix up could involve parallel imports

 
• By Francesca Bruce

The UK's medicines regulator, the MHRA, is investigating how rogue cut down blister packs of AstraZeneca's anti-pshycotic Seroquel XL (quetiapine) ended up in Packs of Reckitt Benckiser's Nurofen Plus (ibuprofen plus codeine), a non-prescription analgesic. The MHRA says that the Seroquel blisters were both parallel imports and originator products.

The UK's medicines regulator, the MHRA, is investigating how rogue cut down blister packs of AstraZeneca's anti-pshycotic Seroquel XL (quetiapine) ended up in Packs of Reckitt Benckiser's Nurofen Plus (ibuprofen plus codeine), a non-prescription analgesic. The MHRA says that the Seroquel blisters were both parallel imports and originator products.

At this stage neither company, nor the MHRA, knows exactly what happened. According to Reckitt, the standard blister strips of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

EU 15% Tariff Deal Still Leaves Questions For Pharma

 
• By Jessica Merrill

A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 
• By Andrew McConaghie

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By Kevin Grogan

Comes Days After PDUFA Pushback For GSK's Blenrep.